Open AccessBiological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients
Author(s) -
Raphaëlla Cohen-Sors,
A.C. Fougerousse,
Z. Reguiaï,
F. Maccari,
E. Mahé,
J. Delaunay,
A. Roussel,
M. Amy de la Bretèque,
Caroline Cottencin,
A. Bertolotti,
H. Kemp,
G. Chaby
Publication year - 2021
Publication title -
clinical, cosmetic and investigational dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 35
ISSN - 1178-7015
DOI - 10.2147/ccid.s320098
Subject(s) - medicine , psoriasis , population , retrospective cohort study , apremilast , malignancy , family history , surgery , dermatology , psoriatic arthritis , environmental health
Few studies addressing the safety and efficacy of biological therapy (BT) or apremilast (APR) in patients with psoriasis with a history of hematologic malignancy (HM) exist.